You are here

Fasenra

AstraZeneca, working to grow Fasenra’s reach, touts positive trial against GSK's Nucala in new use

AstraZeneca, working to grow Fasenra’s reach, touts positive trial against GSK's Nucala in new use

Fierce Pharma

clinical trials

eosinophilic asthma

Flag link:

AstraZeneca’s Fasenra meets primary endpoint in Phase III rare vasculitis trial

AstraZeneca’s Fasenra meets primary endpoint in Phase III rare vasculitis trial

Clinical Trials Arena

eosinophilic granulomatosis with polyangiitis

clinical trials

Flag link:

Weak data for Fasenra undermine AZ’s ambitions for the drug

Weak data for Fasenra undermine AZ’s ambitions for the drug

Pharmaphorum

eosinophilic asthma

chronic rhinosinusitis with nasal polyps

eosinophilic esophagitis

Flag link:

AstraZeneca debuts annoying purple ‘Phil’ creatures, personified asthma eosinophils ‘behaving badly’

AstraZeneca debuts annoying purple ‘Phil’ creatures, personified asthma eosinophils ‘behaving badly’

Endpoints

pharma marketing

DTC advertising

eosinophilic asthma

Flag link:

FDA says no to AZ’s Fasenra for nasal polyp indication

FDA says no to AZ’s Fasenra for nasal polyp indication

Pharmaforum

Flag link:

AstraZeneca's Fasenra spares asthma patients from steroid use in large trial

AstraZeneca's Fasenra spares asthma patients from steroid use in large trial

Fierce Pharma

clinical trials

Flag link:

AstraZeneca's asthma drug succeeds late-stage study

AstraZeneca's asthma drug succeeds late-stage study

Reuters

clinical trials

Flag link:

FDA green lights AstraZeneca's asthma drug Fasenra for self-administration

FDA green lights AstraZeneca's asthma drug Fasenra for self-administration

Yahoo/Reuters

Flag link:

AstraZeneca’s Fasenra gets FDA ODD status for eosinophilic oesophagitis

AstraZeneca’s Fasenra gets FDA ODD status for eosinophilic oesophagitis

Pharmaceutical Business Review

eosinophilic esophagitis

Flag link:

AstraZeneca respiratory business gets boost from 3-drug inhaler results

AstraZeneca respiratory business gets boost from 3-drug inhaler results

Yahoo/Reuters

Flag link:

AstraZeneca's Fasenra offers severe asthma patients 2 years of benefits: analysis

AstraZeneca's Fasenra offers severe asthma patients 2 years of benefits: analysis

Fierce Pharma

clinical trials

Flag link:

AstraZeneca’s asthma drug Fasenra looks promising for a set of rare chronic immune diseases

AstraZeneca’s asthma drug Fasenra looks promising for a set of rare chronic immune diseases

Endpoints

Flag link:

Astrazeneca's Fasenra Gets Orphan Drug Designation for Autoimmune Disease

Astrazeneca's Fasenra Gets Orphan Drug Designation for Autoimmune Disease

Yahoo/Zacks.com

eosinophilic granulomatosis with polyangiitis

Flag link:

AstraZeneca, shut out of COPD, touts long-term Fasenra asthma data

AstraZeneca, shut out of COPD, touts long-term Fasenra asthma data

Fierce Pharma

Flag link:

NICE says yes to AstraZeneca’s Fasenra, but only when its GSK rival can’t be used

NICE says yes to AstraZeneca’s Fasenra, but only when its GSK rival can’t be used

Fierce Pharma

Flag link:

AstraZeneca drug Fasenra fails to achieve main goal in COPD trial

AstraZeneca drug Fasenra fails to achieve main goal in COPD trial

Yahoo/Reuters

clinical trials

Flag link:

AstraZeneca's Fasenra (benralizumab) Fails Ph III Trial for COPD

AstraZeneca's Fasenra (benralizumab) Fails Ph III Trial for COPD

CP Wire

Flag link:

AstraZeneca's Fasenra (benralizumab) Fails Ph III Trial for COPD

Flag link:

Drugmakers take to Japan: 3 new drug approvals won by AstraZeneca, Merck, and EA Pharma

Drugmakers take to Japan: 3 new drug approvals won by AstraZeneca, Merck, and EA Pharma

Endpoints

Flag link:

GlaxoSmithKline's Nucala, buoyed by its medical organization, ready to 'fiercely compete' with AstraZeneca

GlaxoSmithKline's Nucala, buoyed by its medical organization, ready to 'fiercely compete' with AstraZeneca

Fierce Pharma

eosinophilic asthma

Flag link: